socalTECH

SEPTEMBER 20, 2010

Los Angeles-based Internet Brands , which operates a suite of online, advertising driven websites across a wide range of verticals, said Monday that it would go private in a $640M, private equity deal, bucking the trend of Southern California companies filing to get to the public markets.

Internet Brands 190

Internet Brands Westlake Village Woodland Hills Beverly Hills 190

Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? The presidential race captivated millions of TV viewers this week as the first debate took place in Hofstra. But biotech watchers had other races on their mind.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

The company shares rights to its lead drug enzalutamide (Xtandi) with Astellas Pharma and its second drug, talazoparib, a type of cancer treatment called a PARP inhibitor, awaits crucial Phase 3 data next year. The company gave no reason for the rejection. Whether Medivation will be worth the price remains to be seen.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 22, 2016

The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes the gig, and the strategic direction he or she chooses for Biogen will have implications not just for the company and its employees, but the sector overall.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. Verily is the biotech group at Google’s parent company Alphabet (NASDAQ: [[ticker:GOOG:]]). Instead, Holmes promoted a new system, MiniLab , in development. Regeneron is paying $25 million upfront.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. The full data set has yet to be released.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67